Mylan (NASDAQ:MYL) – Equities researchers at Leerink Swann upped their Q4 2018 EPS estimates for Mylan in a research note issued on Monday, April 16th. Leerink Swann analyst A. Fadia now forecasts that the company will earn $1.80 per share for the quarter, up from their previous estimate of $1.30. Leerink Swann currently has a “Outperform” rating and a $44.00 target price on the stock.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, February 28th. The company reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.02. The business had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The business’s revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.57 EPS.
NASDAQ:MYL opened at $40.74 on Wednesday. The firm has a market cap of $20,961.91, a PE ratio of 8.93, a PEG ratio of 1.30 and a beta of 1.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.13 and a quick ratio of 0.73. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82.
In other Mylan news, insider Anthony Mauro sold 12,257 shares of Mylan stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.35, for a total value of $494,569.95. Following the completion of the sale, the insider now owns 147,435 shares in the company, valued at approximately $5,949,002.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert J. Coury sold 150,000 shares of Mylan stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $40.10, for a total value of $6,015,000.00. The disclosure for this sale can be found here. Insiders sold a total of 269,287 shares of company stock valued at $11,034,960 in the last 90 days. 0.69% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of MYL. Ameriprise Financial Inc. grew its holdings in shares of Mylan by 16.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 326,281 shares of the company’s stock worth $10,228,000 after purchasing an additional 46,853 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Mylan by 20.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock worth $111,450,000 after purchasing an additional 612,513 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Mylan by 56.5% during the 3rd quarter. Janus Henderson Group PLC now owns 114,620 shares of the company’s stock worth $3,593,000 after purchasing an additional 41,389 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Mylan by 127.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 20,641 shares of the company’s stock worth $648,000 after purchasing an additional 11,553 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Mylan by 170.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 137,725 shares of the company’s stock worth $5,827,000 after purchasing an additional 86,888 shares during the period. Institutional investors and hedge funds own 84.53% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/04/19/mylan-expected-to-earn-q4-2018-earnings-of-1-80-per-share-myl.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.